Bioq Pharma Inc., of San Francisco, expanded its license and supply agreement with Sandoz, a division of Basel, Switzerland-based Novartis AG, under which Sandoz has the right to exclusively market an additional ready-to-use infusible sedative, AS-2, in the U.S. Under the agreement, Bioq is responsible for developing and supplying the unit dose infusion pharmaceutical, and Sandoz is responsible for obtaining regulatory approval, marketing and commercializing the product. Financial terms were not disclosed.